Literature DB >> 12629080

Increased osteoprotegerin serum levels in men with coronary artery disease.

Michael Schoppet1, Alexander M Sattler, Juergen R Schaefer, Matthias Herzum, Bernhard Maisch, Lorenz C Hofbauer.   

Abstract

Osteoprotegerin (OPG) regulates osteoclast and immune functions and appears to represent a protective factor for the vascular system. However, the role of OPG in human atherosclerosis has not been evaluated. In this study, we assessed OPG serum levels in 522 age-matched men who, on the basis of coronary angiography, had either absence of coronary artery disease (CAD) or presence of single-vessel disease, double-vessel disease, or severe triple-vessel disease. OPG serum levels were positively correlated with age (r = 0.28; P < 0.001) and were higher in men with diabetes mellitus (P < 0.01). OPG serum levels in men without CAD were 5.4 +/- 2.0 pmol/liter, compared with 6.1 +/- 2.1 pmol/liter in single-vessel disease (P < 0.005), 5.9 +/- 2.4 in double-vessel disease (P < 0.05), and 6.3 +/- 2.3 pmol/liter in triple-vessel disease (P < 0.001). Moreover, OPG serum levels were positively correlated with the severity of CAD as determined by a CAD scoring system (r = 0.17; P < 0.01). In conclusion, our data underline that OPG serum levels are associated with the severity of CAD and are increased in elderly men and patients with diabetes mellitus. We conclude that increased OPG serum levels may reflect advanced cardiovascular disease in men.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12629080     DOI: 10.1210/jc.2002-020775

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  75 in total

1.  Cholesterol in vascular and valvular calcification.

Authors:  L L Demer
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

2.  Osteoprotegerin is not associated with angiographic coronary calcification.

Authors:  Prospero B Gogo; David J Schneider; Edward F Terrien; Burton E Sobel; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

3.  Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension.

Authors:  Amit Noheria; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2010-03-25       Impact factor: 2.689

Review 4.  Vascular calcification: pathobiology of a multifaceted disease.

Authors:  Linda L Demer; Yin Tintut
Journal:  Circulation       Date:  2008-06-03       Impact factor: 29.690

Review 5.  The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification.

Authors:  Linda Demer; Yin Tintut
Journal:  Circ Res       Date:  2011-06-10       Impact factor: 17.367

6.  Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus.

Authors:  A N Kiani; P Aukrust; T Ueland; I Hollan; E Barr; L S Magder; M Petri
Journal:  Lupus       Date:  2016-12-06       Impact factor: 2.911

7.  Adverse effects of hyperlipidemia on bone regeneration and strength.

Authors:  Flavia Pirih; Jinxiu Lu; Fei Ye; Olga Bezouglaia; Elisa Atti; Maria-Grazia Ascenzi; Sotirios Tetradis; Linda Demer; Tara Aghaloo; Yin Tintut
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

8.  Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis.

Authors:  Yu Asanuma; Cecilia P Chung; Annette Oeser; Joseph F Solus; Ingrid Avalos; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Tuulikki Sokka; Theodore Pincus; C Michael Stein
Journal:  Atherosclerosis       Date:  2007-06-14       Impact factor: 5.162

Review 9.  Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link?

Authors:  W Jeffcoate
Journal:  Diabetologia       Date:  2004-08-21       Impact factor: 10.122

10.  Clinical, microbiological, and salivary biomarker profiles of dental implant patients with type 2 diabetes.

Authors:  Nikolaos Tatarakis; Janet S Kinney; Marita Inglehart; Thomas M Braun; Charles Shelburne; Niklaus P Lang; William V Giannobile; Tae-Ju Oh
Journal:  Clin Oral Implants Res       Date:  2013-02-27       Impact factor: 5.977

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.